TRDAEntrada Therapeutics, Inc.

$502M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M

Gross Profit

$2M8.5% margin

Operating Income

-$6M-22.9% margin

Net Income

-$7M-26.4% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$203M

Free Cash Flow

$202M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$476M

Total Liabilities

$246M

Stockholders' Equity

$230M

Cash & Equivalents

$228M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$0	—
Gross Profit	$2M	$0	—
Operating Income	-$6M	-$22M	+73.9%
Net Income	-$7M	-$22M	+69.2%

Revenue Segments

License

$212M100%

TRDA Q1 2023 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena